Scientists from the University of Leicester have successfully trialled a new pill that reduces asthma attacks by targeting airway muscles.
The experimental drug Fevipiprant “is the first oral treatment for asthma in 20 years”, says the Press Association.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Professor Chris Brightling, from the University of Leicester, said: “Our research shows for the first time that Fevipiprant not only reduces inflammation in the airways, but also reduces the amount of muscle in the lining of the airway. This is likely to explain some of the effects seen in the symptoms and breathing tests following treatment.”
He added: “Our findings suggest that Fevipiprant could have positive long-term effects upon the progression of the disease through remodelling, as well as improve symptoms and reduce attacks.”
The asthma drug “specifically blocks the activation of a muscle protein, which reduces the movement of the immature muscle cells from forming a bundle and blocking the airway”, says Sky News.
There are more than 300 million people who are affected by asthma worldwide and the number is increasing. In the UK there are roughly around 500,000 people who have moderate to severe forms of asthma.
Currently “there are no drugs available on the NHS which treat the build-up of smooth muscle mass as a method of reducing asthma symptoms”, adds Sky News.
For people with severe asthma, “a procedure called thermoplasty, which uses thermal energy to decrease the amount of smooth muscle in the airways, may be offered”, says Medical Xpress. This requires “sedation in hospital and is not a cure, nor suitable for everyone”, the website adds.
Most people in the UK affected by asthma are able to routinely manage the condition with inhaled drugs and steroids.
But Fevipiprant could offer sufferers a way to avoid some of the side-effects associated with using steroids including weight gain.
Dr Himanshu Kaul, a postdoctoral fellow in the School of Biomedical Engineering at the University of British Columbia who helped with the trial, said: "Our computer model represents a milestone towards patient-specific models in respiratory medicine that has the potential to help design new drugs and optimise existing therapies."
-
5 hastily redrawn cartoons about redistrictingCartoons Artists take on Donald Trump's draughtsmanship, the White House ballroom, and more
-
Bonnie Blue: taking clickbait to extremesTalking Point Channel 4 claims documentary on the adult performer's attention-grabbing sex stunts is opening up a debate
-
Broccoli and lentil salad with curried tahini and dates recipeThe Week Recommends Flavoursome and healthy, this creamy salad is perfect as part of a mezze
-
Why the FDA wants to restrict kratom-related productsIn the Spotlight The compound is currently sold across the United States
-
US overdose deaths plunged 27% last yearspeed read Drug overdose still 'remains the leading cause of death for Americans aged 18-44,' said the CDC
-
Trump seeks to cut drug prices via executive orderspeed read The president's order tells pharmaceutical companies to lower prescription drug prices, but it will likely be thrown out by the courts
-
FDA approves painkiller said to thwart addictionSpeed Read Suzetrigine, being sold as Journavx, is the first new pharmaceutical pain treatment approved by the FDA in 20 years
-
The UK's first legal drug consumption roomThe Explainer 'Potentially transformative moment in UK drugs policy' as The Thistle opens in Glasgow
-
Drugmakers paid pharmacy benefit managers to avoid restricting opioid prescriptionsUnder the radar The middlemen and gatekeepers of insurance coverage have been pocketing money in exchange for working with Big Pharma
-
ADHD drugs shortage: what's behind it?The Explainer Supply chain issues and 'tripling' of prescriptions concerns GPs as problems getting medication become 'desperate'
-
Cannabinoid hyperemesis syndrome: a rare health complication putting chronic cannabis users at riskThe Explainer The illness is sending some chronic marijuana users to emergency care for painful persistent vomiting
